896 abstracts found.



Results filter

Molecular pathology: the genomic basis of cancer

Year:

Session type:

Reinhard Buettner1
CIOCologne University Hospital and Center for Integrated Oncology

Break-induced replication mediates repair of collapsed DNA replication forks and tandem duplications in cancer cells

Year:

Session type:

Thanos Halazonetis1
1University of Geneva, Geneva, Switzerland

Genomics, integromics and the role of molecular pathology

Year:

Session type:

Manuel Salto-Tellez1
1Queen’s University Belfast and Belfast Health and Social Care Trust, Belfast, UK

Introduction: Targeting Ras

Year:

Session type:

Julian Downward1
1Cancer Research UK London Research Institute, London, UK

Renewed efforts to target Ras directly: the NCI Ras Program

Year:

Session type:

Dominic Esposito1
1Frederick National Laboratory for Cancer Research, Frederick, MD, USA

A phase 1, dose escalation study of paclitaxel with GSK1120212 (trametinib) for the treatment of advanced melanoma

Year:

Session type:

Nicholas Coupe1, Pippa Corrie2, Mirela Hategan2, James Larkin3, Martin Gore3, Avinash Gupta1, Adelyn Wise4, Sam Suter1, Cristian Ciria5, Sharon Love5, Linda Collins4, Mark Middleton1,6
1Oxford University Hospitals NHS Trust, Oxford, UK,2Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,3The Royal Marsden Hospital NHS Foundation Trust, London, UK,4Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK,5Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, University of Oxford, Oxford, UK,6NIHR Oxford Biomedical Research Centre, Oxford, UK

Prospective, multi-centre, case-control study to evaluate a novel Cytosponge™–TFF3 test for diagnosing Barrett’s oesophagus

Year:

Session type:

Caryn Ross-Innes1, Irene Debiram-Beecham1, Maria O’Donovan2, Elaine Walker1, Sibu Varghese1, Pierre Lao-Sirieix1, Laurence Lovat3, Michael Griffin4, Krish Ragunath5, Rehan Haidry3, Sarmed Sami5, Philip Kaye5, Marco Novelli3, Babett Disep4, Richard Ostler6, Benoit Aigret6, Bernard North6, Peter Sasieni6, Rebecca Fitzgerald1, BEST2 Study Group7

1MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge, UK,2Department Histopathology, Addenbrooke’s Hospital, Cambridge, UK,3University College London Hospital, London, UK,4Royal Victoria Infirmary, Newcastle upon Tyne, UK,5Nottingham Queen’s Medical Centre, Nottingham, UK,6Cancer Prevention Trials Unit, London, UK,7Multi-centre BEST2 Study group, England, UK


Chemical biological modulation of Ras signalling

Year:

Session type:

Herbert Waldmann1
1Max Planck Institute of Molecular Physiology, Dortmund, Germany

Introduction: Genetically engineered mouse models (GEMM) of cancer: how have they performed?

Year:

Session type:

Owen Sansom1
1Cancer Research UK Beatson Institute, Glasgow, UK

Searching for novel therapeutic approaches to RAS, the commonest and least tractable oncogene

Year:

Session type:

Julian Downward1
1Cancer Research UK London Research Institute, London, UK

Developing integrin alpha-v beta-6 as a therapeutic target for high-risk breast cancer

Year:

Session type:

Kate M Moore1, Gareth T Thomas2, Syed Haider3, Stephen Duffy1, Simon T Barry4, Louise Jones1, John F Marshall1
1Barts Cancer Institute, London, UK,2University of Southampton, Southampton, UK,3Department of Oncology, Oxford, UK,4AstraZeneca/Medimmune, Macclesfield, UK

Introduction: Thinking beyond the androgen receptor: a new horizon in castrate-resistant prostate cancer

Year:

Session type:

David Waugh1
1Queen’s University, Belfast, UK

Fly approach to cancer therapeutics

Year:

Session type:

Ross Cagan1
1Icahn School of Medicine at Mount Sinai, New York, NY, USA

Targeting DNA repair and transcriptional interplay in prostate cancer: mechanisms and implications for disease progression

Year:

Session type:

Karen Knudsen1
1Thomas Jefferson University, Philadelphia, PA, USA

Introduction: Metabolic adaptations of cancer

Year:

Session type:

Eyal Gottlieb1
1Cancer Research UK Beatson Institute, Glasgow, UK

Optimal radiation targeting of PTEN deficiency in castrate resistant prostate cancer in combination with modulators of DNA damage and repair

Year:

Session type:

Conor Hanna1, Steven Walker1, Karl Butterworth1, Nuala McCabe1, Richard Kennedy1, Kevin Prise1
1Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast, UK

De novo purine biosynthesis dictates glutamine dependency of glioblastoma cells

Year:

Session type:

Eyal Gottlieb1
1Cancer Research UK Beatson Institute, Glasgow, UK

Tracking genomic aberrations of the androgen receptor (AR) in castration-resistant prostate cancer (CRPC)

Year:

Session type:

Gerhardt Attard1,2
1The Institute of Cancer Research, London, UK,2Royal Marsden NHS Foundation Trust, London, UK

Fatty acid binding protein 4 – a point of convergence for angiogenic and metabolic signalling pathways in endothelial cells

Year:

Session type:

Ulrike Harjes1, Esther Bridges1, Alan McIntyre1, Barbara Fielding1,2, Adrian Harris1
1WIMM, University of Oxford, Oxford, UK,2OCDEM, University of Oxford, Oxford, UK,3University of Surrey, Surrey, UK

Molecular profiling of castration-resistant prostate cancer

Year:

Session type:

Tapio Visakorpi1
1University of Tampere, Tampere, Finland

Metabolic transformation of fumarate hydratase-deficient cancer cells

Year:

Session type:

Christian Frezza1
1MRC Cancer Unit, University of Cambridge, Cambridge, UK

Introduction: Biology of the radiation response

Year:

Session type:

W Gillies McKenna1
1Cancer Research UK and Medical Research Council Oxford Institute, Oxford, UK

Introduction: Pancreatic cancer: from basic science to clinical implementation

Year:

Session type:

Claus Jorgensen1
1Cancer Research UK Manchester Institute, Manchester, UK

Using mouse models to explore stromal composition and function

Year:

Session type:

Ben Z Stanger1
1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

CXCL12 expression by FAP+ stromal cells is associated with a paucity of CD3+ T-cells in human pancreatic adenocarcinoma and may offer a target for drug treatment

Year:

Session type:

Tobias Janowitz1, Claire Connell1, Christine Feig1, James Jones1, Matthew Kraman1, Richard Wells1, Edward Roberts1, David Tuveson1, Douglas Fearon1, Duncan Jodrell1
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

Reciprocal tumour-stroma signalling in pancreatic ductal adenocarcinoma

Year:

Session type:

Claus Jorgensen1
1Cancer Research UK Manchester Institute, Manchester, UK

Clinical relevance of genomic aberrations in pancreatic cancer

Year:

Session type:

Andrew V Biankin1
1Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK

Tumour cell density (TCD) as a continuous histological measure of downstaging efficacy in the preoperative chemoradiation (CRT) of locally advanced rectal cancer (LARC): Relationship to survival

Year:

Session type:

Ravi Kodavatiganti1, Nicholas West2, Emma Tinkler-Hundal2, Philip Quirke2, Simon Gollins1
1North Wales Cancer Treatment Centre, Denbighshire, UK,2University of Leeds, Leeds, UK

ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR)

Year:

Session type:

Helena Earl1,2, Louise Hiller3, Janet Dunn3, Clare Blenkinsop3, Louise Grybowicz4, Anne-Laure Vallier4, Jean Abraham1,5, Jeremy Thomas6, Elena Provenzano2,5, Luke Hughes-Davies5, Karen McAdam7, Stephen Chan8, Rizvana Ahmad9, Tamas Hickish10, Stephen Houston11, Daniel Rea12, John Bartlett13,14, Carlos Caldas1,15, David Cameron14, Larry Hayward6

1Department of Oncology, University of Cambridge, Cambridge, UK,2NIHR Cambridge Biomedical Research Centre, Cambridge, UK,3Warwick Clinical Trials Unit, University of Warwick, Coventry, UK,4Cambridge Clinical Trials Unit − Cancer Theme, Cambridge, UK,5Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,6Western General Hospital, Edinburgh, UK,7Peterborough City Hospital, Peterborough, UK,8Nottingham University Hospital City Campus, Nottingham, UK,9West Middlesex University Hospital, Isleworth, UK,10Royal Bournemouth Hospital, Bournemouth University, Bournemouth, UK,11Royal Surrey County Hospital, Guildford, UK,12Sandwell&West Birmingham NHS Trust; University Hospital Birmingham NHS Trust, Birmingham, UK,13Ontario Institute for Cancer Research, Ontario, Canada,14Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, UK,15Cancer Research UK Cambridge Research Institute, Cambridge, UK


EGF-coated gold nanoparticles (EGF-Au NPs) provide an efficient nano-scale delivery approach to the molecular radiotherapy of EGFR-positive cancer

Year:

Session type:

Lei Song1, Sarah Able1, Phoebe Lam1, Christopher Hillyar1, Georgina Royle1, Katherine Vallis1
1CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK

REST- A Dutch/UK randomized phase III trial on the use of thoracic radiotherapy in extensive stage small-cell lung cancer

Year:

Session type:

Corinne Faivre-Finn1, Matthew Hatton2, Michael Snee3, Pooja Jain4, Paula Wilson5, Rhona McMenemin6, Clive Peedell7, Andrew Bates8, Angel Garcia9, Janet Ironside10, Sally Falk1, Harm van Tinteren11, Astrid Keijser12, Ben Slotman13

1The Christie NHS Foundation Trust, Manchester, UK,2Weston Park Hospital, Sheffield, UK,3St James’s University Hospital, Leeds, UK,4Clatterbridge Centre for Oncology, Wirral, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne, UK,7James Cook University Hospital, Middlesbrough, UK,8Southampton General Hospital, Southampton, UK,9North Wales Cancer Centre, Glan Clwyd Hospital, Rhyl, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11Netherlands Cancer Institute, Amsterdam, The Netherlands,12IKNL Clinical Research Department, Amsterdam, The Netherlands,13VU University Medical Center, Amsterdam, The Netherlands


MOPq10 plus synchronous radiation as a possible alternative to 5FU/Mitomycin/Radiation

Year:

Session type:

Tim Oliver1, Karen Tipples1
1Barts Cancer Institute, London, UK

ET: A randomised, multicentre, phase III trial to evaluate ERCC1 as a predictive biomarker for comparing platinum with nonplatinum chemotherapy, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)

Year:

Session type:

Siow-Ming Lee1,15, Fiona Blackhall2, Abhro Chaudhuri3, Gary Middleton4, Samreen Ahmed5, Jonathan Hicks6, Barbara Crosse7, James Spicer8, Mark Napier9, Julian Singer10, Marianne Nicolson11, David Ferry12, Conrad Lewanski13, Sally Ann Rolls14, Mary Falzon1, Yenting Ngai15, Rachel Lillywhite15, Natasha Iles15, Robin Rudd15, Allan Hackshaw15

1University College London Hospital, London, UK,2Christie Hospital Manchester, Manchester, UK,3Lincoln County Hospital, Lincoln, UK,4Royal Surrey County Hospital, Guildford, UK,5Leicester Royal Infirmary, Leicester, UK,6New Victoria Hospital, Kingston upon Thames, UK,7Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, UK,8Guys Hospital London, London, UK,9North Devon District Hospital, Barnstaple, UK,10Princess Alexandra Hospital, Harlow, UK,11Aberdeen Royal Infirmary, Aberdeen, UK,12New Cross Hospital Birmingham, Birmingham, UK,13Charing Cross Hospital, London, UK,14Withybush General Hospital, Haverfordwest, UK,15University College London, London, UK


The Poly (ADP-Ribose) Polymerase (PARP) inhibtor ABT-888 increases the theraputeic efficacy of 131I-A5B7 anti-CEA radioimmunotherapy in two distinct models of colorectal cancer.

Year:

Session type:

Vineeth Rajkumar1, Carine Neier2, Iva Trenevska1, Vessela Vassileva1, Mathew Robson1, Geoffrey Boxer1, Dario Neri2, Barbara Pedley1
1University College London, London, UK,2ETH, Zurich, Switzerland

Outcome of patients with serous papillary endometrial cancer: 5 year experience in a single institution

Year:

Session type:

Alison Stillie1, Philippa Boothroyd2
1Edinburgh Cancer Centre, Edinburgh, UK,2University of Edinburgh Medical School, Edinburgh, UK

MicroRNA-187 modulates radiosensitivity in oesophageal adenocarcinoma

Year:

Session type:

Niamh Lynam-Lennon1, Ann-Marie Mongan1, Becky Bibby2, Laure Marignol1, Jacintha O'Sullivan1, John Reynolds1, Stephen Maher1,2
1University of Dublin, Trinity College, Dublin, Ireland,2University of Hull, Hull, UK

FLT PET-CT and response prediction to neoadjuvant chemotherapy in primary breast cancer

Year:

Session type:

David Woolf1, Mark Beresford2, Sonia Li1, Mitch Dowsett3, Bal Sanghera1, Wai-Lup Wong1, Luke Sonoda1, Simone Detre3, Vishal Amin1, Mei-Lin Ah-See1, David Miles1, Andreas Makris1
1Mount Vernon Cancer Centre, Northwood, UK,2Royal United Hospital Bath, Bath, UK,3Royal Marsden Hospital, London, UK

Hypo-fractionated versus Standard Fractionated Radical Radiotherapy for Non-Melanoma Skin cancer

Year:

Session type:

Syed Tirmazy1, Shahid Gilani1, Murray Brunt1
1University Hospital of North Staffordshire, Stoke-on-Trent, UK

Lack of association between 76 Prostrte cancer risk SNPs and likelihood of radiation toxicity suggests individuals can have standard Radiation

Year:

Session type:

Mahbubl Ahmed1, Leila Dorling2,1, Gillian Barnett2, West Catherine3, Burnet Neil2, Paul Pharoah2, Ros Eeles1
1Institute of Cancer Research, London, UK,2University of Cambridge, Cambridge, UK,3University of Manchester, Manchester, UK

Definitive treatment of locally advanced oropharyngeal cancer with proton pencil-beam scanning and requirement for adaptive re-planning: the potential impact of anatomic changes on doses to targets and organs at risk

Year:

Session type:

David Thomson1,2, Boon-Keng Kevin Teo2, Ashley Ong2,3, Khong Wei Ang2,3, Maura Kirk2, Peter Ahn2, Tim Solberg2, Nick Slevin1, Alexander Lin2
1The Christie NHS Foundation Trust, Manchester, UK,2University of Pennsylvania, Philadelphia, USA,3National Cancer Centre Singapore, Singapore, Singapore

Final Results of the SONATINA Clinical Trial of Oral Nelfinavir Before and During Radiotherapy for T3-4 Rectal Cancer

Year:

Session type:

Esme Hill1,2, Monica Enescu2, Corran Roberts2, Nicholas West3, Jamie Franklin2, Lai-Mun Wang1,2, Lucy Boyle2, Kwun-Ye Chu1,2, Thomas MacGregor2, Claire Blesing1, Somnath Mukherjee1,2, Ewan Anderson1, Sharon Love2, Julia Schnabel2, Philip Quirke3, Mike Partridge2, Ricky Sharma1,2

1Oxford University Hospitals NHS Trust, Oxford, UK,2University of Oxford, Oxford, UK,3Leeds Institute of Molecular Medicine, Leeds, UK


FLT PET CT to assess early response to treatment in oropharyngeal cancer

Year:

Session type:

Rachel Pearson1,2, George Petrides3, Andrew McQueen3, Ross Maxwell1, Ruth Plummer1,2, Herbie Newell1, Charles Kelly2, Jim Snell2
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,2Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK,3Department of Radiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

The SYmptom Study of radioThErapy in MeSothelioma (SYSTEMS), a multi centre phase II study assessing the role of palliative radiotherapy for pain control in mesothelioma

Year:

Session type:

Nick MacLeod1,2, Noelle O'Rourke2, Alan Price1,3, John Sheridan4, Karen Moore2, Lynn McMahon2, Diann Taggart2, Jon Stobo2, Caroline Bray2, Anthony Chalmers2,5, Marie Fallon1,3, Barry Laird1,3
1University of Edinburgh, Edinburgh, UK,2Beatson West of Scotland Cancer Centre, Glasgow, UK,3Western General Hospital, Edinburgh, UK,4Gartnavel General Hospital, Glasgow, UK,5University of Glasgow, Glasgow, UK

Use of PET-CT derived biomarkers in prognostication for anal cancer

Year:

Session type:

Ee Siang Choong1, Patricia Arce-Calisaya1, Nathalie Casanova1, Mark Teo1, Rachel Cooper1, David Sebag-Montefiore1, Andrew Scarsbrook1
1St James Institute of Oncology, Leeds, UK

Instruments to record acute and late adverse events (AE) associated with radical prostate cancer treatment for remote monitoring in clinical practice: A systematic review of randomised controlled trials (RCT)

Year:

Session type:

Trish Holch1,2, Galina Velikova1,2, Ann Henry2, Kevin Franks2, Alex Gilbert1,2, Abigail Albutt1, Emma Ingleson1, Susan Davidson3, Jacki Routledge3
1University of Leeds, Leeds, West Yorks, UK,2Leeds Teaching Hospitals Trust, Leeds, West Yorks, UK,3The Christie NHS Foundation Trust, Manchester, Lancashire, UK

Risk of second malignancy following prostate radiotherapy using contemporary radiotherapy techniques

Year:

Session type:

Louise Murray1,2, Christopher Thompson3, John Lilley3, Vivian Cosgrove3, Kevin Franks1, David Sebag-Montefiore1,2, Ann Henry1,2
1Radiotherapy Research Group, Leeds Cancer Centre, Leeds, UK,2University of Leeds, Leeds, UK,3Department of Medical Physics, Leeds Cancer Centre, Leeds, UK

Adjuvant use of brachytherapy in endometrial carcinoma

Year:

Session type:

Cecilia McCormick1, Khizar Hayat1
1Clatterbridge Cancer Centre, Wirral, UK

Prevalence of HOXB13 G84E germline mutation and prostate cancer risk in the UK; correlation with tumour phenotype

Year:

Session type:

Christos Mikropoulos1, Tokhir Dadaev1, Edward Saunders1, Malgorzata Tymarkiewisz1, Daniel Leongamornlert1, Koveela Govindasami1, Michelle Guy1, David Neal3, Freddy Hamdy4, Antonis Antoniou5, Zsofia Kote-Jarai1, Rosalind Eeles1,2
1Institute of Cancer Research, Sutton, UK,2Royal Marsden Hospital, London, UK,3Addenbrooke's Hospital, Cambridge, UK,4John Radcliffe Hospital, Oxford, UK,5University of Cambridge, Cambridge, UK

Tumour immune-surveillance: a novel epithelial determinant required for the development of signatory murine intestinal intraepithelial T cells

Year:

Session type:

Rafael Di Marco Barros1,3, Livija Deban1,2, Sara Cipolat1,2, Rosie Hart1,2, Pierre Vantourout1,2, Anett Jandke1,2, Lucie Abeler-Dorner1,2, Deena Gibbons1,2, Adrian Hayday1,2
1London Research Institute, London, UK,2King's College, London, UK,3University College London Medical School, London, UK

Optimisation of copy number segmentation of multi-sampled Wilms’ tumours for the interpretation of cancer evolution and genetic biomarker heterogeneity

Year:

Session type:

George Cresswell1, Borbala Mifsud1, Nicholas M. Luscombe1, Kathy Pritchard-Jones2,3, William Mifsud2,3
1London Research Institute, Cancer Research UK, London, UK,2UCL Institute of Child Health, London, UK,3Great Ormond Street Hospital, London, UK